Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (13)
Michael Weiner, Jonathan Cummins, Annaswamy Raji, Susan Ofner, Kristy Iglay, Evgenia Teal, Xiaochun Li, Samuel S. Engel, Kristina Knapp, Swapnil Rajpathak, Jarod Baker, Arnaub K. Chatterjee & Larry Radican. (2020) A randomized study on the usefulness of an electronic outpatient hypoglycemia risk calculator for clinicians of patients with diabetes in a safety-net institution. Current Medical Research and Opinion 36:4, pages 583-593.
Read now
Read now
Haoda Fu, Junxiang Luo & Yongming Qu. (2016) Hypoglycemic events analysis via recurrent time-to-event (HEART) models. Journal of Biopharmaceutical Statistics 26:2, pages 280-298.
Read now
Read now
Christopher Sorli & Michael K Heile. (2014) Identifying and meeting the challenges of insulin therapy in type 2 diabetes. Journal of Multidisciplinary Healthcare 7, pages 267-282.
Read now
Read now
Michael L. Ganz, Neil S. Wintfeld, Qian Li, Yuan-Chi Lee, Elyse Gatt & Joanna C. Huang. (2014) Severe hypoglycemia rates and associated costs among type 2 diabetics starting basal insulin therapy in the United States. Current Medical Research and Opinion 30:10, pages 1991-2000.
Read now
Read now
Stephen A. Brunton. (2012) Hypoglycemic Potential of Current and Emerging Pharmacotherapies in Type 2 Diabetes Mellitus. Postgraduate Medicine 124:4, pages 74-83.
Read now
Read now
Morgan Bron, Maryna Marynchenko, Hongbo Yang, Andrew P. Yu & Eric Q. Wu. (2012) Hypoglycemia, Treatment Discontinuation, and Costs in Patients with Type 2 Diabetes Mellitus on Oral Antidiabetic Drugs. Postgraduate Medicine 124:1, pages 124-132.
Read now
Read now
Carrie Fidler, Torsten Elmelund Christensen & Samantha Gillard. (2011) Hypoglycemia: An overview of fear of hypoglycemia, quality-of-life, and impact on costs. Journal of Medical Economics 14:5, pages 646-655.
Read now
Read now
Torsten E. Christensen, Jens Gundgaard & Trine Pilgaard. (2011) Healthcare costs of fast-acting insulin analogues versus short-acting human insulin for Danish patients with type 2 diabetes on a basal–bolus regimen. Journal of Medical Economics 14:4, pages 477-485.
Read now
Read now
Sandra L. Tunis & Michael E. Minshall. (2010) Self-monitoring of blood glucose (SMBG) for type 2 diabetes patients treated with oral anti-diabetes drugs and with a recent history of monitoring: cost-effectiveness in the US. Current Medical Research and Opinion 26:1, pages 151-162.
Read now
Read now
Meaghan St. Charles, Michael E. Minshall, Bhavik J. Pandya, Robert W. Baran & Sandra L. Tunis. (2009) A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US. Current Medical Research and Opinion 25:6, pages 1343-1353.
Read now
Read now
Stanislav Goykhman, Andjela Drincic, Jean Claude Desmangles & Marc Rendell. (2009) Insulin Glargine: a review 8 years after its introduction. Expert Opinion on Pharmacotherapy 10:4, pages 705-718.
Read now
Read now
Sandra L. Tunis, Michael E. Minshall, Meaghan St. Charles, Bhavik J. Pandya & Robert W. Baran. (2008) Pioglitazone versus rosiglitazone treatment in patients with type 2 diabetes and dyslipidemia: cost-effectiveness in the US
. Current Medical Research and Opinion 24:11, pages 3085-3096.
Read now
Read now
Craig J. Currie, Chris D. Poole, Tony Tetlow, Paul Holmes & Phil McEwan. (2007) The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis. Current Medical Research and Opinion 23:sup1, pages S33-S39.
Read now
Read now
Articles from other publishers (31)
Michael Weiner, Philip Adeoye, Margaret J. Boeh, Kunal Bodke, Jessica Broughton, Anietra R. Butler, Mackenzie L. Dafferner, Lindsay A. Dirlam, Denisha Ferguson, Amanda L. Keegan, NiCole R. Keith, Joy L. Lee, Corrina B. McCorkle, Daniel G. Pino, Mu Shan, Preethi Srinivas, Qing Tang, Evgenia Teal, Wanzhu Tu, April Savoy, Christopher M. Callahan & Daniel O. Clark. (2022) Continuous Glucose Monitoring and Other Wearable Devices to Assess Hypoglycemia among Older Adult Outpatients with Diabetes Mellitus. Applied Clinical Informatics 14:01, pages 037-044.
Crossref
Crossref
Javier Morales & Doron Schneider. (2014) Hypoglycemia. The American Journal of Medicine 127:10, pages S17-S24.
Crossref
Crossref
Lin XieSteve ZhouBrett W. PinskyErin K. BuysmanOnur Baser. (2014) Impact of Initiating Insulin Glargine Disposable Pen Versus Vial/Syringe on Real-World Glycemic Outcomes and Persistence Among Patients with Type 2 Diabetes Mellitus in a Large Managed Care Plan: A Claims Database Analysis. Diabetes Technology & Therapeutics 16:9, pages 567-575.
Crossref
Crossref
Julio Rosenstock, Vivian Fonseca, Stefan Schinzel, Marie-Paule Dain, Peter Mullins & Matthew Riddle. (2014) Reduced risk of hypoglycemia with once-daily glargine versus twice-daily NPH and number needed to harm with NPH to demonstrate the risk of one additional hypoglycemic event in type 2 diabetes: Evidence from a long-term controlled trial. Journal of Diabetes and its Complications 28:5, pages 742-749.
Crossref
Crossref
A. Liebl, H. Andersen, A. L. Svendsen, J. Vora & J.-F. Yale. (2013) Resource utilisation and quality of life following initiation of insulin detemir in patients with type 2 diabetes mellitus. International Journal of Clinical Practice 67:8, pages 740-749.
Crossref
Crossref
Marie Jakobsen, Mette Dalsgaard, Morten Hørmann & Daniél Vega Møller. (2012) Insulin analogues dosing and costs - comparing real-life daily doses of insulin detemir and insulin glargine in type 2 diabetes patients. BMC Endocrine Disorders 12:1.
Crossref
Crossref
A. Penfornis, E. Personeni, M. Tiv, C. Monnier, L. Meillet, J. Combes, C. Mouret & S. Picard. (2012) Quality of care of patients with type 1 diabetes: Population-based results in a French region. Diabetes & Metabolism 38:5, pages 436-443.
Crossref
Crossref
Robert J. Ligthelm, Marcel Kaiser, Jiten Vora & Jean-François Yale. (2012) Insulin Use in Elderly Adults: Risk of Hypoglycemia and Strategies for Care. Journal of the American Geriatrics Society 60:8, pages 1564-1570.
Crossref
Crossref
G. G. Rhoads, M. P. Dain, Q. Zhang & L. Kennedy. (2011) Two-year glycaemic control and healthcare expenditures following initiation of insulin glargine versus neutral protamine Hagedorn insulin in type 2 diabetes. Diabetes, Obesity and Metabolism 13:8, pages 711-717.
Crossref
Crossref
Philip A. Levin, Quanwu Zhang, James H. Mersey, Francis Y. Lee, Lee A. Bromberger, Madhu Bhushan & Rajat Bhushan. (2011) Glycemic Control With Insulin Glargine Plus Insulin Glulisine Versus Premixed Insulin Analogues in Real-World Practices: A Cost-Effectiveness Study With a Randomized Pragmatic Trial Design. Clinical Therapeutics 33:7, pages 841-850.
Crossref
Crossref
Setareh A. Williams, Michael F. Pollack & Marco DiBonaventura. (2011) Effects of hypoglycemia on health-related quality of life, treatment satisfaction and healthcare resource utilization in patients with type 2 diabetes mellitus. Diabetes Research and Clinical Practice 91:3, pages 363-370.
Crossref
Crossref
Sundar S. ShresthaPing ZhangLawrence BarkerGiuseppina Imperatore. (2010) Medical Expenditures Associated With Diabetes Acute Complications in Privately Insured U.S. Youth. Diabetes Care 33:12, pages 2617-2622.
Crossref
Crossref
Jens Gundgaard, Torsten E. Christensen & Trine Lyager Thomsen. (2010) Direct healthcare costs of patients with type 2 diabetes using long-acting insulin analogues or NPH insulin in a basal insulin-only regimen. Primary Care Diabetes 4:3, pages 165-172.
Crossref
Crossref
Won Chan Lee, Christopher Conner & Mette Hammer. (2010) Results of a model analysis of the cost-effectiveness of liraglutide versus exenatide added to metformin, glimepiride, or both for the treatment of type 2 diabetes in the United States. Clinical Therapeutics 32:10, pages 1756-1767.
Crossref
Crossref
Susan Cornell. (2010) Managing diabetes-related costs and quality of life issues: Value of insulin analogs and pens for inpatient use. Health Policy 96:3, pages 191-199.
Crossref
Crossref
Lauren J. Lee, Andrew P. Yu, Scott J. Johnson, Howard G. Birnbaum, Pavel Atanasov, Don P. Buesching, Jeffrey A. Jackson & Jaime A. Davidson. (2010) Direct costs associated with initiating NPH insulin versus glargine in patients with type 2 diabetes: A retrospective database analysis. Diabetes Research and Clinical Practice 87:1, pages 108-116.
Crossref
Crossref
Meaghan St Charles, Peter Lynch, Claudia Graham & Michael E. Minshall. (2009) A Cost-Effectiveness Analysis of Continuous Subcutaneous Insulin Injection versus Multiple Daily Injections in Type 1 Diabetes Patients: A Third-Party US Payer Perspective. Value in Health 12:5, pages 674-686.
Crossref
Crossref
Bijan J. Borah, Theodore Darkow, Jonathan Bouchard, Mark Aagren, Felicia Forma & Berhanu Alemayehu. (2009) A comparison of insulin use, glycemic control, and health care costs with insulin detemir and insulin glargine in insulin-naive patients with type 2 diabetes. Clinical Therapeutics 31:3, pages 623-631.
Crossref
Crossref
P. Levin. (2008) The cost-effectiveness of insulin glargine vs. neutral protamine Hagedorn insulin in type 2 diabetes: a focus on health economics. Diabetes, Obesity and Metabolism 10:s2, pages 66-75.
Crossref
Crossref
Jerry Meece. (2008) Effect of insulin pen devices on the management of diabetes mellitus. American Journal of Health-System Pharmacy 65:11, pages 1076-1082.
Crossref
Crossref
Patrick J. Boyle & John Zrebiec. (2008) Impact of therapeutic advances on hypoglycaemia in type 2 diabetes. Diabetes/Metabolism Research and Reviews 24:4, pages 257-285.
Crossref
Crossref
Steven Leichter. (2008) Is the use of insulin analogues cost-effective?. Advances in Therapy 25:4, pages 285-299.
Crossref
Crossref
Alan J. Garber, Per Clauson, Claus B. Pedersen & Klaus Kølendorf. (2007) Lower Risk of Hypoglycemia with Insulin Detemir than with Neutral Protamine Hagedorn Insulin in Older Persons with Type 2 Diabetes: A Pooled Analysis of Phase III Trials. Journal of the American Geriatrics Society 55:11, pages 1735-1740.
Crossref
Crossref
Linda B. Haas. (2007) Optimizing Insulin Use in Type 2 Diabetes: Role of Basal and Prandial Insulin in Long-Term Care Facilities. Journal of the American Medical Directors Association 8:8, pages 502-510.
Crossref
Crossref
Carlos Campos. (2007) Addressing Cultural Barriers to the Successful Use of Insulin in Hispanics with Type 2 Diabetes. Southern Medical Journal 100:8, pages 812-820.
Crossref
Crossref
David Cobden, Won Chan Lee, Sanjeev Balu, Ashish V Joshi & Chris L Pashos. (2007) Health Outcomes and Economic Impact of Therapy Conversion to a Biphasic Insulin Analog Pen Among Privately Insured Patients with Type 2 Diabetes Mellitus. Pharmacotherapy 27:7, pages 948-962.
Crossref
Crossref
Donald R. Miller, John A. Gardner, Ann M. Hendricks, Quanwu Zhang & Benjamin G. Fincke. (2007) Health care resource utilization and expenditures associated with the use of insulin glargine. Clinical Therapeutics 29:3, pages 478-487.
Crossref
Crossref
Michael F. Bullano, Maxine D. Fisher, W. Daniel Grochulski, Laura Menditto & Vincent J. Willey. (2006) Hypoglycemic events and glycosylated hemoglobin values in patients with type 2 diabetes mellitus newly initiated on insulin glargine or premixed insulin combination products. American Journal of Health-System Pharmacy 63:24, pages 2473-2482.
Crossref
Crossref
Won Chan Lee, Sanjeev Balu, David Cobden, Ashish V. Joshi & Chris L. Pashos. (2006) Medication adherence and the associated health-economic impact among patients with type 2 diabetes mellitus converting to insulin pen therapy: An analysis of third-party managed care claims data. Clinical Therapeutics 28:10, pages 1712-1725.
Crossref
Crossref
William J. Valentine, Andrew J. Palmer, Katrina M. Erny-Albrecht, Joshua A. Ray, David Cobden, Volker Foos, Francisco M. Lurati & Stéphane Roze. (2006) Cost-effectiveness of basal insulin from a US health system perspective: Comparative analyses of detemir, glargine, and NPH. Advances in Therapy 23:2, pages 191-207.
Crossref
Crossref
B. Guerci & J.P. Sauvanet. (2005) Subcutaneous insulin: pharmacokinetic variability and glycemic variability. Diabetes & Metabolism 31:4, pages 4S7-4S24.
Crossref
Crossref